{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T23:07:52Z","timestamp":1766012872071,"version":"3.37.3"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T00:00:00Z","timestamp":1680048000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Medical Research Future Fund - Targeted Health System and Community Organisation Research","award":["RGMS ID: 1175082"],"award-info":[{"award-number":["RGMS ID: 1175082"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Trials"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Introduction<\/jats:title>\n                <jats:p>Melanoma surveillance photography (MSP) is a comprehensive surveillance method that comprises two- or three-dimensional total body photography with tagged digital dermoscopy, performed at prescribed intervals. It has the potential to reduce unnecessary biopsies and enhance early detection of melanoma, but it is not yet standard care for all high-risk patients in Australia. This protocol describes a randomised controlled trial (RCT) designed to evaluate the clinical impact and cost-effectiveness of using MSP for the surveillance of individuals at ultra-high or high risk of melanoma from a health system perspective.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods and design<\/jats:title>\n                <jats:p>This is a registry-based, unblinded, multi-site, parallel-arm RCT that will be conducted over 3\u00a0years. We aim to recruit 580 participants from three Australian states: Victoria, New South Wales and Queensland, via state cancer registries or direct referral from clinicians. Eligible participants within 24\u00a0months of a primary cutaneous melanoma diagnosis will be randomised 1:1 to receive either MSP in addition to their routine clinical surveillance (intervention group) or routine clinical surveillance without MSP (control group). Most participants will continue surveillance with their usual care provider, and the frequency of follow-up visits in both groups will depend on the stage of their primary melanoma and risk factors. The primary outcome measure of the study is the number of unnecessary biopsies (i.e. false positives, being cases where a lesion is biopsied due to suspected melanoma on clinical examination, either with or without MSP, but the resulting histopathology finding is negative for melanoma). Secondary outcomes include the evaluation of health economic outcomes, quality of life and patient acceptability. Two sub-studies will explore the benefit of MSP in high-risk patients prior to a melanoma diagnosis and the diagnostic performance of MSP in the teledermatology setting compared to the en face clinical setting.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Discussion<\/jats:title>\n                <jats:p>This trial will determine the clinical efficacy, cost-effectiveness and affordability of MSP to facilitate policy decision-making at the national and local levels, across primary and specialist care.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>ClinicalTrials.gov <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04385732\">NCT04385732<\/jats:ext-link>. Registered on May 13, 2020.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13063-023-07203-5","type":"journal-article","created":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T13:03:39Z","timestamp":1680095019000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Study protocol for a randomised controlled trial to evaluate the use of melanoma surveillance photography to the Improve early detection of MelanomA in ultra-hiGh and high-risk patiEnts (the IMAGE trial)"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4700-3781","authenticated-orcid":false,"given":"Mabel K.","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne E.","family":"Cust","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Peter","family":"Soyer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monika","family":"Janda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katja","family":"Loewe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gabrielle","family":"Byars","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"Fishburn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paul","family":"White","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rashidul Alam","family":"Mahumud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robyn P. M.","family":"Saw","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Herschtal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pablo","family":"Fernandez-Penas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pascale","family":"Guitera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachael L.","family":"Morton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rory","family":"Wolfe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria J.","family":"Mar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,3,29]]},"reference":[{"key":"7203_CR1","unstructured":"Australian Institute of Health Welfare. Cancer data in Australia. Canberra: AIHW; 2021. Available at https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/summary."},{"key":"7203_CR2","unstructured":"Australian Institute of Health Welfare. Skin cancer in Australia. Canberra: AIHW; 2016. Available at https:\/\/www.aihw.gov.au\/reports\/cancer\/cancer-data-in-australia\/contents\/summary."},{"issue":"6","key":"7203_CR3","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1007\/s40258-017-0341-y","volume":"15","author":"TM Elliott","year":"2017","unstructured":"Elliott TM, Whiteman DC, Olsen CM, Gordon LG. Estimated healthcare costs of melanoma in Australia over 3 years post-diagnosis. Appl Health Econ Health Policy. 2017;15(6):805\u201316.","journal-title":"Appl Health Econ Health Policy"},{"issue":"6","key":"7203_CR4","doi-asserted-by":"publisher","first-page":"472","DOI":"10.3322\/caac.21409","volume":"67","author":"JE Gershenwald","year":"2017","unstructured":"Gershenwald JE, Scolyer RA, Hess KR, Sondak VK, Long GV, Ross MI, et al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J Clin. 2017;67(6):472\u201392. https:\/\/doi.org\/10.3322\/caac.21409.","journal-title":"CA Cancer J Clin."},{"key":"7203_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.3389\/fmed.2018.00152","volume":"5","author":"JE Rayner","year":"2018","unstructured":"Rayner JE, Laino AM, Nufer KL, Adams L, Raphael AP, Menzies SW, et al. Clinical perspective of 3D total body photography for early detection and screening of melanoma. Front Med (Lausanne). 2018;5:152.","journal-title":"Front Med (Lausanne)."},{"issue":"3","key":"7203_CR6","first-page":"669","volume":"159","author":"ME Vestergaard","year":"2008","unstructured":"Vestergaard ME, Macaskill P, Holt PE, Menzies SW. Dermoscopy compared with naked eye examination for the diagnosis of primary melanoma: a meta-analysis of studies performed in a clinical setting. Br J Dermatol. 2008;159(3):669\u201376.","journal-title":"Br J Dermatol"},{"issue":"1","key":"7203_CR7","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1159\/000517900","volume":"238","author":"K Grochulska","year":"2022","unstructured":"Grochulska K, Betz-Stablein B, Rutjes C, Chiu FPC, Menzies SW, Soyer HP, et al. The additive value of 3D total body imaging for sequential monitoring of skin lesions: a case series. Dermatology. 2022;238(1):12\u20137.","journal-title":"Dermatology"},{"issue":"1","key":"7203_CR8","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1200\/JCO.2016.68.4308","volume":"35","author":"CG Watts","year":"2017","unstructured":"Watts CG, Cust AE, Menzies SW, Mann GJ, Morton RL. Cost-effectiveness of skin surveillance through a specialized clinic for patients at high risk of melanoma. J Clin Oncol. 2017;35(1):63\u201371.","journal-title":"J Clin Oncol"},{"issue":"2","key":"7203_CR9","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s40258-017-0368-0","volume":"16","author":"CG Watts","year":"2018","unstructured":"Watts CG, Wortley S, Norris S, Menzies SW, Guitera P, Askie L, et al. A national budget impact analysis of a specialised surveillance programme for individuals at very high risk of melanoma in Australia. Appl Health Econ Health Policy. 2018;16(2):235\u201342.","journal-title":"Appl Health Econ Health Policy"},{"key":"7203_CR10","unstructured":"Cancer Council Australia Melanoma Guidelines Working Party. Clinical practice guidelines for the diagnosis and management of melanoma. Sydney: Cancer Council. Australia; 2018.Available at https:\/\/wiki.cancer.org.au\/australia\/Guidelines:Melanoma."},{"key":"7203_CR11","unstructured":"Medical Services Advisory Committee. Public summary document - application no. 1356 - Melanoma surveillance photography - total body photography and digital dermoscopy.: In: Committee. MSA, editor. Canberra 2017.; 2017. Available at http:\/\/www.msac.gov.au\/internet\/msac\/publishing.nsf\/Content\/1356-public."},{"key":"7203_CR12","doi-asserted-by":"publisher","first-page":"e7586","DOI":"10.1136\/bmj.e7586","volume":"346","author":"A-W Chan","year":"2013","unstructured":"Chan A-W, Tetzlaff JM, G\u00f8tzsche PC, Altman DG, Mann H, Berlin JA, et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ British Med J. 2013;346:e7586.","journal-title":"BMJ British Med J."},{"issue":"5","key":"7203_CR13","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1111\/bjd.18524","volume":"182","author":"AE Cust","year":"2020","unstructured":"Cust AE, Badcock C, Smith J, Thomas NE, Haydu LE, Armstrong BK, et al. A risk prediction model for the development of subsequent primary melanoma in a population-based cohort. Br J Dermatol. 2020;182(5):1148\u201357.","journal-title":"Br J Dermatol"},{"issue":"8","key":"7203_CR14","doi-asserted-by":"publisher","first-page":"889","DOI":"10.1001\/jamadermatol.2016.0939","volume":"152","author":"K Vuong","year":"2016","unstructured":"Vuong K, Armstrong BK, Weiderpass E, Lund E, Adami HO, Veierod MB, et al. Development and external validation of a melanoma risk prediction model based on self-assessed risk factors. JAMA Dermatol. 2016;152(8):889\u201396.","journal-title":"JAMA Dermatol"},{"issue":"Supppl 4","key":"7203_CR15","doi-asserted-by":"publisher","first-page":"S125","DOI":"10.1016\/S0959-8049(01)00448-8","volume":"38","author":"P Fayers","year":"2002","unstructured":"Fayers P, Bottomley A. Quality of life research within the EORTC-the EORTC QLQ-C30. Eur Org Res Treatment Cancer. Eur J Cancer. 2002;38(Supppl 4):S125-33.","journal-title":"Eur J Cancer."},{"issue":"11","key":"7203_CR16","doi-asserted-by":"publisher","first-page":"499","DOI":"10.5694\/mja2.50207","volume":"210","author":"R Mercieca-Bebber","year":"2019","unstructured":"Mercieca-Bebber R, Costa DS, Norman R, Janda M, Smith DP, Grimison P, et al. The EORTC Quality of Life Questionnaire for cancer patients (QLQ-C30): Australian general population reference values. Med J Aust. 2019;210(11):499\u2013506.","journal-title":"Med J Aust"},{"issue":"12","key":"7203_CR17","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1007\/s40273-014-0193-3","volume":"32","author":"R Faria","year":"2014","unstructured":"Faria R, Gomes M, Epstein D, White IR. A guide to handling missing data in cost-effectiveness analysis conducted within randomised controlled trials. Pharmacoeconomics. 2014;32(12):1157\u201370.","journal-title":"Pharmacoeconomics"}],"container-title":["Trials"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13063-023-07203-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13063-023-07203-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,29]],"date-time":"2023-03-29T13:06:47Z","timestamp":1680095207000},"score":1,"resource":{"primary":{"URL":"https:\/\/trialsjournal.biomedcentral.com\/articles\/10.1186\/s13063-023-07203-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,29]]},"references-count":17,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["7203"],"URL":"https:\/\/doi.org\/10.1186\/s13063-023-07203-5","relation":{},"ISSN":["1745-6215"],"issn-type":[{"type":"electronic","value":"1745-6215"}],"subject":[],"published":{"date-parts":[[2023,3,29]]},"assertion":[{"value":"20 March 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 March 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study has been reviewed and approved by Alfred Hospital Ethics Committee (HREC\/59606\/Alfred-2020). Written informed consent will be obtained from all recruited participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The study results will be made available to participants and disseminated through peer-reviewed publications, conferences and media outlets. Participants are asked to provide optional consent to the use of their non-identifiable images for presentations and publications and\/or the use of their images (including their face, but no other identifiable information) for further research.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"RPMS has received honoraria for advisory board participation from MSD, Novartis and Qbiotics and speaking honoraria from BMS and Novartis. HPS is a shareholder of MoleMap NZ Limited and e-derm consult GmbH and undertakes regular teledermatological reporting for both companies. HPS is a medical consultant for Canfield Scientific Inc., MoleMap Australia Pty Ltd., Blaze Bioscience Inc. and a Medical Advisor for First Derm. PG receives some honoraria from Metaoptima, CA.The other authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}